Table 2.
Effects of systemic LPS administration on lung and brain IDO1 activity and hepatic TDO activity in gerbils, Sprague-Dawley rats and C57BL/6 J mice.
| Saline | Enzyme activity | ||
|---|---|---|---|
|
|
|||
| LPS | |||
|
|
|||
| 1 mg/kg | 50 mg/kg | ||
| Lung IDO1 (nmol/g/h) | |||
| Gerbil | 78 ± 13 | 2,303 ± 340* | – |
| Rat | 5.9 ± 3.0 | 15.0 ± 3.2* | 6.9 ± 3.0 |
| Mouse | 178.5 ± 33.4 | 3161.2 ± 501.9*,# | – |
| Brain IDO1 (nmol/g/h) | |||
| Gerbil | 2.1 ± 0.5 | 6.95 ± 1.1* | – |
| Rat | <0.1 | <0.1 | <0.1 |
| Mouse | 12.2 ± 1.7 | 36.9 ± 3.2*,# | – |
| TDO (μmol/g/h) | |||
| Gerbil | 0.96 ± 0.08 | 0.71 ± 0.7 | – |
| Rat | 2.2 ± 0.2 | 2.7 ± 0.3 | 2.2 ± 0.1 |
| Mouse | 2.4 ± 0.1 | 1.6 ± 0.2*,# | – |
Notes: LPS was administered by intraperitoneal injection (i.p.), and samples were collected 24 h later. Control animals received saline vehicle. Data are mean ± SEM values.
*
Significant differences from respective control by one-way ANOVA and Dunnett’s t test9 or Scheffe’s F post-hoc test.25
#
Mice were administered 10 μg LPS in 200 μL saline by i.p. injection. Estimated dose of LPS is much lower than 1 mg/kg (approximately 0.4 to 0.5 mg/kg).